Evidence map›Paper›PMID 39976800›Full record

ArticleStem cell reviews and reports2025

Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Systemic Lupus Erythematosus via Glucose Metabolism of CD4

Meng Ding, Lu Jin, Shaoxin Cui, Lin Yang, Jingjing He, Xiaoping Wang, Fei Chang, Qun Wang, Xue Liu, Hongtao Jin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Meng Ding *Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Lu Jin *Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Shaoxin Cui *Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Lin Yang *Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Jingjing HeDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Xiaoping WangDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Fei ChangDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Qun WangDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Xue LiuDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Hongtao JinDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Shuran SongDepartment of Clinical Laboratory, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Min ShiDepartment of Clinical Laboratory, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Jingjing YuDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Jun MaDepartment of Anatomy, Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Aijing LiuDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China. Laj111@126.com.ORCID 0000-0002-5762-5592

Funding

Hebei Provincial Department of Science and Technology 19277721DNatural Science Foundation of Hebei Province H2019206387, H2023206264)
6 · The paper itself

Abstract

backgroundT cells play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE), with their functions regulated by various metabolic pathways. This study explores SLE pathogenesis and the therapeutic effects of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) via metabolic reprogramming.

methodsClinical data and peripheral blood samples were collected from 15 SLE patients and matched healthy controls. CD4

resultsCompared to healthy controls, activated CD4

conclusionhUC-MSCs inhibited the proliferation and function of aberrant CD4

Indexed as

CD4-Positive T-LymphocytesGlucoseLupus Erythematosus, SystemicMesenchymal Stem CellsMesenchymal Stem Cell TransplantationUmbilical CordAdultAnimalsCoculture TechniquesFemaleHumansMaleMiceSignal TransductionGlucoseCD4+ T lymphocytesGlycolysisMesenchymal stem cellsMetabolic reprogrammingmRNASystemic lupus erythematosus

Identifiers

PMID39976800
PMCPMC12102139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.